ICD-10-PCS FY2022 code changes

ICD-10-PCS update effective October 1, 2021: 191 new codes, 107 deleted, 62 revised titles. Compared with FY2021 (January 1, 2021). CMS replaced the October 2021 order file with the April 1, 2022 one. Rebuilt by reversing the official April 1, 2022 order addenda (7 codes, plus 2 in the January 12, 2022 errata).

Other ICD-10-PCS releases: FY2027, FY2026 (April 1, 2026), FY2026, FY2025 (April 1, 2025), FY2025, FY2024 (April 1, 2024), FY2024, FY2023 (April 1, 2023), FY2023, FY2022 (April 1, 2022), FY2021 (January 1, 2021), FY2021, FY2020 (August 1, 2020), FY2020, FY2019, FY2018, FY2017.

Also in this release: ICD-10-CM changes.

New codes (191)

• 00D00ZZ Extraction of Brain, Open Approach
• 00D03ZZ Extraction of Brain, Percutaneous Approach
• 00D04ZZ Extraction of Brain, Percutaneous Endoscopic Approach
• 00D70ZZ Extraction of Cerebral Hemisphere, Open Approach
• 00D73ZZ Extraction of Cerebral Hemisphere, Percutaneous Approach
• 00D74ZZ Extraction of Cerebral Hemisphere, Percutaneous Endoscopic Approach
• 02C03Z7 Extirpation of Matter from Coronary Artery, One Artery, Orbital Atherectomy Technique, Percutaneous Approach
• 02C13Z7 Extirpation of Matter from Coronary Artery, Two Arteries, Orbital Atherectomy Technique, Percutaneous Approach
• 02C23Z7 Extirpation of Matter from Coronary Artery, Three Arteries, Orbital Atherectomy Technique, Percutaneous Approach
• 02C33Z7 Extirpation of Matter from Coronary Artery, Four or More Arteries, Orbital Atherectomy Technique, Percutaneous Approach
• 02F03ZZ Fragmentation in Coronary Artery, One Artery, Percutaneous Approach
• 02F13ZZ Fragmentation in Coronary Artery, Two Arteries, Percutaneous Approach
• 02F23ZZ Fragmentation in Coronary Artery, Three Arteries, Percutaneous Approach
• 02F33ZZ Fragmentation in Coronary Artery, Four or More Arteries, Percutaneous Approach
• 02RA0LZ Replacement of Heart with Biologic and Synthetic Substitute, Autoregulated Electrohydraulic, Open Approach
• 02RA0MZ Replacement of Heart with Synthetic Substitute, Pneumatic, Open Approach
• 02RH38L Replacement of Pulmonary Valve with Zooplastic Tissue, In Existing Conduit, Percutaneous Approach
• 02RH38M Replacement of Pulmonary Valve with Zooplastic Tissue, Native Site, Percutaneous Approach
• 02VL0CZ Restriction of Left Ventricle with Extraluminal Device, Open Approach
• 02VL0DZ Restriction of Left Ventricle with Intraluminal Device, Open Approach
• 02VL0ZZ Restriction of Left Ventricle, Open Approach
• 02VL3CZ Restriction of Left Ventricle with Extraluminal Device, Percutaneous Approach
• 02VL3DZ Restriction of Left Ventricle with Intraluminal Device, Percutaneous Approach
• 02VL3ZZ Restriction of Left Ventricle, Percutaneous Approach
• 02VL4CZ Restriction of Left Ventricle with Extraluminal Device, Percutaneous Endoscopic Approach
• 02VL4DZ Restriction of Left Ventricle with Intraluminal Device, Percutaneous Endoscopic Approach
• 02VL4ZZ Restriction of Left Ventricle, Percutaneous Endoscopic Approach
• 03173ZF Bypass Right Brachial Artery to Lower Arm Vein, Percutaneous Approach
• 03183ZF Bypass Left Brachial Artery to Lower Arm Vein, Percutaneous Approach
• 03FG3Z0 Fragmentation of Intracranial Artery, Percutaneous Approach, Ultrasonic
• 03FG3ZZ Fragmentation of Intracranial Artery, Percutaneous Approach
• 06LY7CC Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening
• 06LY7CZ Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening
• 06LY7DC Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening
• 06LY7DZ Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening
• 06LY7ZC Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening
• 06LY7ZZ Occlusion of Lower Vein, Via Natural or Artificial Opening
• 06LY8CC Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening Endoscopic
• 06LY8CZ Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening Endoscopic
• 06LY8DC Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic
• 06LY8DZ Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening Endoscopic
• 06LY8ZC Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening Endoscopic
• 06LY8ZZ Occlusion of Lower Vein, Via Natural or Artificial Opening Endoscopic
• 07DT0ZX Extraction of Bone Marrow, Open Approach, Diagnostic
• 07DT0ZZ Extraction of Bone Marrow, Open Approach
• 07DT3ZX Extraction of Bone Marrow, Percutaneous Approach, Diagnostic
• 07DT3ZZ Extraction of Bone Marrow, Percutaneous Approach
• 0F800ZZ Division of Liver, Open Approach
• 0F803ZZ Division of Liver, Percutaneous Approach
• 0F804ZZ Division of Liver, Percutaneous Endoscopic Approach
• 0F810ZZ Division of Right Lobe Liver, Open Approach
• 0F813ZZ Division of Right Lobe Liver, Percutaneous Approach
• 0F814ZZ Division of Right Lobe Liver, Percutaneous Endoscopic Approach
• 0F820ZZ Division of Left Lobe Liver, Open Approach
• 0F823ZZ Division of Left Lobe Liver, Percutaneous Approach
• 0F824ZZ Division of Left Lobe Liver, Percutaneous Endoscopic Approach
• 0K847ZZ Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening
• 0K848ZZ Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening Endoscopic
• 0NH003Z Insertion of Infusion Device into Skull, Open Approach
• 0NH033Z Insertion of Infusion Device into Skull, Percutaneous Approach
• 0NH043Z Insertion of Infusion Device into Skull, Percutaneous Endoscopic Approach
• 0PS403Z Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach
• 0PS443Z Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach
• 0QBN0Z2 Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach
• 0QBN3Z2 Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach
• 0QBN4Z2 Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach
• 0QBP0Z2 Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach
• 0QBP3Z2 Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach
• 0QBP4Z2 Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach
• 0QS003Z Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach
• 0QS043Z Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach
• 0RPJ0J6 Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Open Approach
• 0RPJ0J7 Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Open Approach
• 0RPJ3J6 Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Approach
• 0RPJ3J7 Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Approach
• 0RPJ4J6 Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
• 0RPJ4J7 Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
• 0RPK0J6 Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Open Approach
• 0RPK0J7 Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Open Approach
• 0RPK3J6 Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Approach
• 0RPK3J7 Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Approach
• 0RPK4J6 Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
• 0RPK4J7 Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
• 0RWJ0J6 Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Open Approach
• 0RWJ0J7 Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Open Approach
• 0RWJ3J6 Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Approach
• 0RWJ3J7 Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Approach
• 0RWJ4J6 Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
• 0RWJ4J7 Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
• 0RWJXJ6 Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, External Approach
• 0RWJXJ7 Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, External Approach
• 0RWK0J6 Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Open Approach
• 0RWK0J7 Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Open Approach
• 0RWK3J6 Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Approach
• 0RWK3J7 Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Approach
• 0RWK4J6 Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
• 0RWK4J7 Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
• 0RWKXJ6 Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, External Approach
• 0RWKXJ7 Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, External Approach
• 30233D1 Transfusion of Nonautologous Pathogen Reduced Cryoprecipitated Fibrinogen Complex into Peripheral Vein, Percutaneous Approach
• 30243D1 Transfusion of Nonautologous Pathogen Reduced Cryoprecipitated Fibrinogen Complex into Central Vein, Percutaneous Approach
• 3E1M48X Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach, Diagnostic
• 3E1M48Z Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach
• 4B00XW0 Measurement of Central Nervous Cerebrospinal Fluid Shunt using Wireless Sensor, External Approach
• 5A1221J Performance of Cardiac Output, Continuous, Automated
• BF150ZZ Fluoroscopy of Liver using High Osmolar Contrast
• BF151ZZ Fluoroscopy of Liver using Low Osmolar Contrast
• BF15YZZ Fluoroscopy of Liver using Other Contrast
• BF15ZZA Fluoroscopy of Liver, Guidance
• X2CP3T7 Extirpation of Matter from Abdominal Aorta using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
• X2CQ3T7 Extirpation of Matter from Right Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
• X2CR3T7 Extirpation of Matter from Left Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
• X2CS3T7 Extirpation of Matter from Right Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
• X2CT3T7 Extirpation of Matter from Left Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
• X2CU3T7 Extirpation of Matter from Right Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
• X2CV3T7 Extirpation of Matter from Left Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
• X2CY3T7 Extirpation of Matter from Great Vessel using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
• X2JAX47 Inspection of Heart using Transthoracic Echocardiography, Computer-aided Guidance, New Technology Group 7
• X2KB317 Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
• X2KC317 Bypass Left Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
• X2RX0N7 Replacement of Thoracic Aorta, Arch using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7
• X2V73Q7 Restriction of Coronary Sinus with Reduction Device, Percutaneous Approach, New Technology Group 7
• X2VW0N7 Restriction of Thoracic Aorta, Descending using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7
• XD2G4V7 Monitoring of Upper GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
• XD2G8V7 Monitoring of Upper GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
• XD2H4V7 Monitoring of Lower GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
• XD2H8V7 Monitoring of Lower GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
• XDPH8K7 Irrigation of Lower GI using Intraoperative Single-use Oversleeve, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
• XFJB8A7 Inspection of Hepatobiliary Duct using Single-use Duodenoscope, New Technology Group 7
• XFJD8A7 Inspection of Pancreatic Duct using Single-use Duodenoscope, New Technology Group 7
• XHRPXF7 Replacement of Skin with Bioengineered Allogeneic Construct, External Approach, New Technology Group 7
• XNS00C7 Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7
• XNS03C7 Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7
• XNS40C7 Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7
• XNS43C7 Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7
• XRGA0R7 Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
• XRGA3R7 Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
• XRGA4R7 Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
• XRGB0R7 Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
• XRGB3R7 Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
• XRGB4R7 Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
• XRGC0R7 Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
• XRGC3R7 Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
• XRGC4R7 Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
• XRGD0R7 Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
• XRGD3R7 Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
• XRGD4R7 Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
• XW00X27 Introduction of Bromelain-enriched Proteolytic Enzyme into Skin, External Approach, New Technology Group 7
• XW01397 Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
• XW01X27 Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7
• XW03357 Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW03367 Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW03377 Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW03387 Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033A7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033B7 Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033J7 Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033L7 Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW04357 Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
• XW04367 Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
• XW04377 Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
• XW04387 Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043A7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043B7 Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043L7 Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW0V0P7 Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7
• XW133D7 Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW133E7 Transfusion of Hyperimmune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW143D7 Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
• XW143E7 Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
• XWHD7Q7 Insertion of Neurostimulator Lead into Mouth and Pharynx, Via Natural or Artificial Opening, New Technology Group 7
• XXE0X07 Measurement of Intracranial Vascular Activity, Computer-aided Assessment, New Technology Group 7
• XXE3X27 Measurement of Pulmonary Artery Flow, Computer-aided Triage and Notification, New Technology Group 7
• XXE5XR7 Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7
• XXE5XT7 Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7
• XXE5XV7 Measurement of Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection, New Technology Group 7
• XXE97U7 Measurement of Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, New Technology Group 7
• XY0YX37 Extracorporeal Introduction of Nafamostat Anticoagulant, New Technology Group 7

Deleted codes (107)

• 30230AZ Transfusion of Embryonic Stem Cells into Peripheral Vein, Open Approach
• 30230C0 Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Open Approach
• 30230G0 Transfusion of Autologous Bone Marrow into Peripheral Vein, Open Approach
• 30230G2 Transfusion of Allogeneic Related Bone Marrow into Peripheral Vein, Open Approach
• 30230G3 Transfusion of Allogeneic Unrelated Bone Marrow into Peripheral Vein, Open Approach
• 30230G4 Transfusion of Allogeneic Unspecified Bone Marrow into Peripheral Vein, Open Approach
• 30230H0 Transfusion of Autologous Whole Blood into Peripheral Vein, Open Approach
• 30230H1 Transfusion of Nonautologous Whole Blood into Peripheral Vein, Open Approach
• 30230J0 Transfusion of Autologous Serum Albumin into Peripheral Vein, Open Approach
• 30230J1 Transfusion of Nonautologous Serum Albumin into Peripheral Vein, Open Approach
• 30230K0 Transfusion of Autologous Frozen Plasma into Peripheral Vein, Open Approach
• 30230K1 Transfusion of Nonautologous Frozen Plasma into Peripheral Vein, Open Approach
• 30230L0 Transfusion of Autologous Fresh Plasma into Peripheral Vein, Open Approach
• 30230L1 Transfusion of Nonautologous Fresh Plasma into Peripheral Vein, Open Approach
• 30230M0 Transfusion of Autologous Plasma Cryoprecipitate into Peripheral Vein, Open Approach
• 30230M1 Transfusion of Nonautologous Plasma Cryoprecipitate into Peripheral Vein, Open Approach
• 30230N0 Transfusion of Autologous Red Blood Cells into Peripheral Vein, Open Approach
• 30230N1 Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open Approach
• 30230P0 Transfusion of Autologous Frozen Red Cells into Peripheral Vein, Open Approach
• 30230P1 Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Open Approach
• 30230Q0 Transfusion of Autologous White Cells into Peripheral Vein, Open Approach
• 30230Q1 Transfusion of Nonautologous White Cells into Peripheral Vein, Open Approach
• 30230R0 Transfusion of Autologous Platelets into Peripheral Vein, Open Approach
• 30230R1 Transfusion of Nonautologous Platelets into Peripheral Vein, Open Approach
• 30230S0 Transfusion of Autologous Globulin into Peripheral Vein, Open Approach
• 30230S1 Transfusion of Nonautologous Globulin into Peripheral Vein, Open Approach
• 30230T0 Transfusion of Autologous Fibrinogen into Peripheral Vein, Open Approach
• 30230T1 Transfusion of Nonautologous Fibrinogen into Peripheral Vein, Open Approach
• 30230U2 Transfusion of Allogeneic Related T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach
• 30230U3 Transfusion of Allogeneic Unrelated T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach
• 30230U4 Transfusion of Allogeneic Unspecified T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach
• 30230V0 Transfusion of Autologous Antihemophilic Factors into Peripheral Vein, Open Approach
• 30230V1 Transfusion of Nonautologous Antihemophilic Factors into Peripheral Vein, Open Approach
• 30230W0 Transfusion of Autologous Factor IX into Peripheral Vein, Open Approach
• 30230W1 Transfusion of Nonautologous Factor IX into Peripheral Vein, Open Approach
• 30230X0 Transfusion of Autologous Cord Blood Stem Cells into Peripheral Vein, Open Approach
• 30230X2 Transfusion of Allogeneic Related Cord Blood Stem Cells into Peripheral Vein, Open Approach
• 30230X3 Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Peripheral Vein, Open Approach
• 30230X4 Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Peripheral Vein, Open Approach
• 30230Y0 Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Open Approach
• 30230Y2 Transfusion of Allogeneic Related Hematopoietic Stem Cells into Peripheral Vein, Open Approach
• 30230Y3 Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Peripheral Vein, Open Approach
• 30230Y4 Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Peripheral Vein, Open Approach
• 30240AZ Transfusion of Embryonic Stem Cells into Central Vein, Open Approach
• 30240C0 Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Open Approach
• 30240G0 Transfusion of Autologous Bone Marrow into Central Vein, Open Approach
• 30240G2 Transfusion of Allogeneic Related Bone Marrow into Central Vein, Open Approach
• 30240G3 Transfusion of Allogeneic Unrelated Bone Marrow into Central Vein, Open Approach
• 30240G4 Transfusion of Allogeneic Unspecified Bone Marrow into Central Vein, Open Approach
• 30240H0 Transfusion of Autologous Whole Blood into Central Vein, Open Approach
• 30240H1 Transfusion of Nonautologous Whole Blood into Central Vein, Open Approach
• 30240J0 Transfusion of Autologous Serum Albumin into Central Vein, Open Approach
• 30240J1 Transfusion of Nonautologous Serum Albumin into Central Vein, Open Approach
• 30240K0 Transfusion of Autologous Frozen Plasma into Central Vein, Open Approach
• 30240K1 Transfusion of Nonautologous Frozen Plasma into Central Vein, Open Approach
• 30240L0 Transfusion of Autologous Fresh Plasma into Central Vein, Open Approach
• 30240L1 Transfusion of Nonautologous Fresh Plasma into Central Vein, Open Approach
• 30240M0 Transfusion of Autologous Plasma Cryoprecipitate into Central Vein, Open Approach
• 30240M1 Transfusion of Nonautologous Plasma Cryoprecipitate into Central Vein, Open Approach
• 30240N0 Transfusion of Autologous Red Blood Cells into Central Vein, Open Approach
• 30240N1 Transfusion of Nonautologous Red Blood Cells into Central Vein, Open Approach
• 30240P0 Transfusion of Autologous Frozen Red Cells into Central Vein, Open Approach
• 30240P1 Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open Approach
• 30240Q0 Transfusion of Autologous White Cells into Central Vein, Open Approach
• 30240Q1 Transfusion of Nonautologous White Cells into Central Vein, Open Approach
• 30240R0 Transfusion of Autologous Platelets into Central Vein, Open Approach
• 30240R1 Transfusion of Nonautologous Platelets into Central Vein, Open Approach
• 30240S0 Transfusion of Autologous Globulin into Central Vein, Open Approach
• 30240S1 Transfusion of Nonautologous Globulin into Central Vein, Open Approach
• 30240T0 Transfusion of Autologous Fibrinogen into Central Vein, Open Approach
• 30240T1 Transfusion of Nonautologous Fibrinogen into Central Vein, Open Approach
• 30240U2 Transfusion of Allogeneic Related T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach
• 30240U3 Transfusion of Allogeneic Unrelated T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach
• 30240U4 Transfusion of Allogeneic Unspecified T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach
• 30240V0 Transfusion of Autologous Antihemophilic Factors into Central Vein, Open Approach
• 30240V1 Transfusion of Nonautologous Antihemophilic Factors into Central Vein, Open Approach
• 30240W0 Transfusion of Autologous Factor IX into Central Vein, Open Approach
• 30240W1 Transfusion of Nonautologous Factor IX into Central Vein, Open Approach
• 30240X0 Transfusion of Autologous Cord Blood Stem Cells into Central Vein, Open Approach
• 30240X2 Transfusion of Allogeneic Related Cord Blood Stem Cells into Central Vein, Open Approach
• 30240X3 Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Central Vein, Open Approach
• 30240X4 Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Central Vein, Open Approach
• 30240Y0 Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Open Approach
• 30240Y2 Transfusion of Allogeneic Related Hematopoietic Stem Cells into Central Vein, Open Approach
• 30240Y3 Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Central Vein, Open Approach
• 30240Y4 Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Central Vein, Open Approach
• 30280B1 Transfusion of Nonautologous 4-Factor Prothrombin Complex Concentrate into Vein, Open Approach
• X2C0361 Extirpation of Matter from Coronary Artery, One Artery using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
• X2C1361 Extirpation of Matter from Coronary Artery, Two Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
• X2C2361 Extirpation of Matter from Coronary Artery, Three Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
• X2C3361 Extirpation of Matter from Coronary Artery, Four or More Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
• XR2G021 Monitoring of Right Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1
• XR2H021 Monitoring of Left Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1
• XW03321 Introduction of Ceftazidime-Avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1
• XW03331 Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1
• XW03341 Introduction of Isavuconazole Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1
• XW03351 Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1
• XW033C3 Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3
• XW04321 Introduction of Ceftazidime-Avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
• XW04331 Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1
• XW04341 Introduction of Isavuconazole Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
• XW04351 Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1
• XW043C3 Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3
• XW23346 Transfusion of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6
• XW23376 Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6
• XW24346 Transfusion of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6
• XW24376 Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6

Revised titles (62)

• 3E00X0M Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach (was: Introduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach)
• 3E0130M Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach)
• 3E0230M Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach)
• 3E0300M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach (was: Introduction of Monoclonal Antibody into Peripheral Vein, Open Approach)
• 3E0330M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach)
• 3E0400M Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach (was: Introduction of Monoclonal Antibody into Central Vein, Open Approach)
• 3E0430M Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach)
• 3E0500M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach (was: Introduction of Monoclonal Antibody into Peripheral Artery, Open Approach)
• 3E0530M Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach)
• 3E0600M Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach (was: Introduction of Monoclonal Antibody into Central Artery, Open Approach)
• 3E0630M Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Central Artery, Percutaneous Approach)
• 3E0930M Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Nose, Percutaneous Approach)
• 3E0970M Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Nose, Via Natural or Artificial Opening)
• 3E09X0M Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach (was: Introduction of Monoclonal Antibody into Nose, External Approach)
• 3E0A30M Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Bone Marrow, Percutaneous Approach)
• 3E0B30M Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Ear, Percutaneous Approach)
• 3E0B70M Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Ear, Via Natural or Artificial Opening)
• 3E0BX0M Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach (was: Introduction of Monoclonal Antibody into Ear, External Approach)
• 3E0C30M Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Eye, Percutaneous Approach)
• 3E0C70M Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Eye, Via Natural or Artificial Opening)
• 3E0CX0M Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach (was: Introduction of Monoclonal Antibody into Eye, External Approach)
• 3E0D30M Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Mouth and Pharynx, Percutaneous Approach)
• 3E0D70M Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Mouth and Pharynx, Via Natural or Artificial Opening)
• 3E0DX0M Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach (was: Introduction of Monoclonal Antibody into Mouth and Pharynx, External Approach)
• 3E0E30M Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Products of Conception, Percutaneous Approach)
• 3E0E70M Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening)
• 3E0E80M Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic (was: Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening Endoscopic)
• 3E0F30M Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Respiratory Tract, Percutaneous Approach)
• 3E0F70M Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening)
• 3E0F80M Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic (was: Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening Endoscopic)
• 3E0G30M Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Upper GI, Percutaneous Approach)
• 3E0G70M Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening)
• 3E0G80M Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic (was: Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening Endoscopic)
• 3E0H30M Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Lower GI, Percutaneous Approach)
• 3E0H70M Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening)
• 3E0H80M Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic (was: Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening Endoscopic)
• 3E0J30M Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Percutaneous Approach)
• 3E0J70M Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening)
• 3E0J80M Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic (was: Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic)
• 3E0K30M Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Genitourinary Tract, Percutaneous Approach)
• 3E0K70M Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening)
• 3E0K80M Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic (was: Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic)
• 3E0L30M Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Pleural Cavity, Percutaneous Approach)
• 3E0L70M Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Pleural Cavity, Via Natural or Artificial Opening)
• 3E0M30M Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Peritoneal Cavity, Percutaneous Approach)
• 3E0M70M Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Peritoneal Cavity, Via Natural or Artificial Opening)
• 3E0N30M Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Male Reproductive, Percutaneous Approach)
• 3E0N70M Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening)
• 3E0N80M Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic (was: Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening Endoscopic)
• 3E0P30M Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Female Reproductive, Percutaneous Approach)
• 3E0P70M Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening)
• 3E0P80M Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic (was: Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening Endoscopic)
• 3E0Q00M Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach (was: Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Open Approach)
• 3E0Q30M Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Percutaneous Approach)
• 3E0Q70M Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Via Natural or Artificial Opening)
• 3E0R30M Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Spinal Canal, Percutaneous Approach)
• 3E0S30M Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Epidural Space, Percutaneous Approach)
• 3E0U30M Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Joints, Percutaneous Approach)
• 3E0V30M Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Bones, Percutaneous Approach)
• 3E0W30M Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Lymphatics, Percutaneous Approach)
• 3E0Y30M Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach (was: Introduction of Monoclonal Antibody into Pericardial Cavity, Percutaneous Approach)
• 3E0Y70M Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening (was: Introduction of Monoclonal Antibody into Pericardial Cavity, Via Natural or Artificial Opening)